Related Experiment Video
Updated: Oct 18, 2025

05:19
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
Published on: July 7, 2023
2.7K
Closed-loop neuromodulation in an individual with treatment-resistant depression
Katherine W Scangos1,2, Ankit N Khambhati3,4, Patrick M Daly3,5
1Weill Institute for Neurosciences, University of California, San Francsico, CA, USA. katherine.scangos@ucsf.edu.
Nature Medicine
|October 5, 2021
Summary
Deep brain stimulation (DBS) shows promise for depression. This study identified a neural biomarker to personalize DBS therapy, leading to rapid and sustained symptom improvement in one patient.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Psychiatry
Background:
- Deep brain stimulation (DBS) is an emerging treatment for severe neuropsychiatric disorders like major depression.
- Optimizing DBS requires identifying neural signals that indicate heightened symptom severity for targeted intervention.
Observation:
- Developed a novel method combining intracranial electrophysiology and focal electrical stimulation.
- Identified a personalized, symptom-specific neural biomarker and optimal stimulation site.
- Implanted a chronic deep brain sensing and stimulation device for closed-loop therapy.
Findings:
- Biomarker-driven closed-loop DBS therapy demonstrated rapid and sustained improvement in depression symptoms.
- The personalized approach successfully adapted stimulation to symptom severity.
- This n-of-1 study provides a proof-of-concept for adaptive DBS in depression.
Implications:
- This personalized, biomarker-guided DBS approach may enhance treatment efficacy for major depression.
- Future research should validate these findings in larger, diverse patient populations.
- The methodology could be adapted for other neurological and psychiatric disorders requiring adaptive neuromodulation.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
436
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
436
Electroconvulsive Therapy
263
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
263
Long-term Depression
2.7K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.7K

